Clinical Study
Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center
Table 1
Patient characteristics.
| | Characteristics | | (%) |
| | Age, years | | | | Range | 53 – 81 | | | Median | 66 | | | PSA before RP | | | | Range | 3.3–58.0 | | | Median | 8.1 | | | ≥5 | 46 | 81% | | <5 | 11 | 19% | | PSA after RP | | | | Range | 0.1–1.8 | | | Median | 0.4 | | | ≥0.2 | 51 | 89% | | <0.2 | 6 | 11% | | Pathological stage | | | | pT2a | 5 | 9% | | pT2b | 8 | 14% | | pT2c | 25 | 44% | | pT3a | 14 | 25% | | pT3b | 5 | 9% | | pT4 | 0 | 0% | | Surgical margins | | | | Positive | 29 | 51% | | Negative | 28 | 49% | | Gleason score | | | | ≤6 | 23 | 40% | | 7 | 32 | 56% | | ≥8 | 2 | 4% | | Type of IMRT | | | | 5 coplanar fields | 45 | 79% | | VMAT (RapidArc) | 12 | 21% | | Androgen deprivation | | | | Yes | 44 | 77% | | Short course (<9 months) | 37 | 65% | | Long course | 7 | 12% | | No | 13 | 23% |
|
|
VMAT: volumetric intensity-modulated arc therapy.
|
